Psoriasis Treatment Companies

Nov 2023AbbVie (US) Reported positive top-line results from a Phase 3 study of their JAK inhibitor Skyrizi® (risankizumab) for improving skin clearance and joint health in patients with moderate-to-severe psoriatic arthritis.Launched online patient support programs and educational resources to empower individuals with psoriasis to manage their condition effectively.

Eli Lilly and Company (US) Received FDA approval for their IL-23 inhibitor Taltz® (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis in adults.Collaborated with dermatology societies and clinics to expand access to their psoriasis treatment options and improve patient care.

Johnson & Johnson (US) Announced positive results from a Phase 2b study of their IL-17A inhibitor Tremfya® (guselkumab) for the treatment of palmoplantar pustulosis, a rare and challenging form of psoriasis.Partnered with patient advocacy groups to raise awareness about different psoriasis types and promote early diagnosis and treatment.

Novartis International AG (Switzerland) Launched their Cosentyx® (secukinumab) in new markets for the treatment of plaque psoriasis and other forms of the condition.Focused on developing next-generation biologics with longer dosing intervals and improved efficacy for optimal disease control.

LEO Pharma A/S (Denmark) Introduced their Enstilar® (calcipotriol) foam as a convenient and effective topical treatment option for mild-to-moderate plaque psoriasis.Invested in research on novel topical formulations and combination therapies for improving treatment outcomes and patient satisfaction.

List of Psoriasis Treatment Key Companies in the Market

• Johnson & Johnson Services, Inc. (US)


• Pfizer Inc. (US)


• LEO Pharma A/S (Denmark)


• Novartis AG (Switzerland)


• Merck & Co., Inc. (US)


• UCB S.A. (Belgium)


• AbbVie Inc. (US)


• Sun Pharmaceutical Industries Ltd. (India)


• Eli Lilly and Company (US)


• Amgen Inc. (US)


• Evelo Biosciences, Inc. (US)